NCT03513848

Morning Light Treatment at Home to Reduce PTSD Symptoms

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Rush University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

There is evidence that some of the circadian photoreceptors, the intrinsically photosensitive retinal ganglion cells (ipRGCs), project directly to the amygdala, an area of the brain implicated in PTSD. Thus, a self-administered morning light treatment at home (shifts clock earlier and stimulates ipRGCs) may be a potentially efficacious adjunctive strategy for reducing PTSD symptoms. This study will test a 4 week daily 1 hour morning light treatment (active vs placebo) in individuals with PTSD. Outcome measures include measures of PTSD and depression.

Conditions

• PTSD

Interventions

Type	Name	Description
DEVICE	Retimer	The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
DEVICE	Retimer placebo	The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.

Timeline

• Start date: 2016-04-01
• Primary completion: 2018-06-27
• Completion: 2018-06-28
• First posted: 2018-05-02
• Last updated: 2019-10-23
• Results posted: 2019-10-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study